RxDoctor Payments Data

Arnold Rivera, MD

Urology · Derby, CTNPI 1477583045

Payments from drug & device makers

$999in general payments, 2019–2025

Across 38 payments — averaging $26.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$360
  • Neotract Inc.$196
  • Procept Biorobotics Corporation$90
  • CSL Behring$84
  • Teleflex LLC$74
  • Pfizer$59
  • plus $136 from 4 others

What the payments were for

  • Travel & lodging$909%
  • Food & beverage$79079%
  • Education$11912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$999 in reported general payments places this provider in the 40th percentile of 156 urology providers in Connecticut.

See all urology providers in Connecticut

Medicare billing

Part B allowed, 2024
$81,793
Medicare patients
224
Services billed
670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron183$185,981
MyrbetriqMirabegron48$56,050
Tadalafil110$20,275
ElmironPentosan Polysulfate Sodium11$12,179
XyostedTestosterone Enanthate14$11,263
Tamsulosin Hcl651$9,989
Testosterone43$8,394
Finasteride494$5,476
Testosterone Cypionate59$3,194
Solifenacin Succinate24$3,146
Silodosin34$2,352
Oxybutynin Chloride100$2,005
Estradiol26$1,986
NitrofurantoinNitrofurantoin Macrocrystal39$1,779
Oxybutynin Chloride ErOxybutynin Chloride40$1,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$360$56,05048 claims
Antares Pharma, Inc.Xyosted$24$11,26314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 156 urology providers in Connecticut.

Other urology in Derby

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →